Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells

Cancer Science

Volumn 104, Issue 3, 2013, Pages 391-397

  Kwon, Oh Hyung ^a   Park, Jong Lyul ^a   Baek, Su Jin ^a   Noh, Seung Moo ^b   Song, Kyu Sang ^b   Kim, Seon Young ^a   Kim, Yong Sung ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACHAETE SCUTE LIKE 2; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; FLUOROURACIL; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84874498527     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12076     Document Type: Article

References (31)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41.
2. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer 2003; 3: 592-600.
3. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-53.
4. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2(Suppl. 1): S4-11.
5. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-13.
6. Kwon OH, Park JL, Kim M et al. Aberrant upregulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer. Biochem Biophys Res Commun 2011; 406: 539-45.
7. Tabu K, Sasai K, Kimura T et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008; 18: 1037-46.
8. Deb-Rinker P, Ly D, Jezierski A, Sikorska M, Walker PR. Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation. J Biol Chem 2005; 280: 6257-60.
9. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000; 20: 429-40.
10. Miyamoto T, Jinno Y, Sasaki T et al. Genomic cloning and localization to chromosome 11p15.5 of the human achaete-scute homolog 2 (ASCL2). Cytogenet Cell Genet 1996; 73: 312-14.
11. van der Flier LG, van Gijn ME, Hatzis P et al. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009; 136: 903-12.
12. Jubb AM, Chalasani S, Frantz GD et al. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 2006; 25: 3445-57.
13. Zhu R, Yang Y, Tian Y et al. Ascl2 Knockdown results in tumor growth arrest by miRNA-302b-related inhibition of colon cancer progenitor cells. PLoS ONE 2012; 7: e32170.
14. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-23.
15. Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16281-6.
16. Chiou SH, Wang ML, Chou YT et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-44.
17. Shin G, Kang TW, Yang S, Baek SJ, Jeong YS, Kim SY. GENT: gene expression database of normal and tumor tissues. Cancer Inform 2011; 10: 149-57.
18. Hermansen SE, Kalstad T, How OJ, Myrmel T. Inflammation and reduced endothelial function in the course of severe acute heart failure. Transl Res 2011; 157: 117-27.
19. de Sousa EMF, Colak S, Buikhuisen J et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011; 9: 476-85.
20. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
21. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
22. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-53.
23. Leis O, Eguiara A, Lopez-Arribillaga E et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31: 1354-65.
24. Noda T, Nagano H, Takemasa I et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100: 1647-58.
25. Kobune M, Chiba H, Kato J et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther 2007; 6: 1774-84.
26. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007; 104: 618-23.
27. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-85.
28. Yuan G, Regel I, Lian F et al. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene 2012; doi: 10.1038/onc.2012.40.
29. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-50.
30. Simon E, Petke D, Boger C et al. The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoS ONE 2012; 7: e35486.
31. Gerger A, Zhang W, Yang D et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 2011; 17: 6934-43.